The goal of symptom relief or cessation is achieved by institution of allergen avoidance measures, pharmacotherapy, immunotherapy, or a combination thereof. The clinician should ask about nasal, palate, and eye symptoms, so that pharmacotherapy can be selected to target all of the affected areas. Common non-nasal symptoms contribute to impaired quality of life but may be unintentionally overlooked.
Allergen avoidance is one of the guiding principles of treatment. While environmental control measures can sometimes lead to complete symptom control (e.g., by removing a pet), they can at other times be difficult to implement.
After an initial pharmacological treatment regimen has been initiated, follow-up should occur within 7-14 days and therapy be stepped up or stepped down as deemed necessary.[60]Bousquet J, Schünemann HJ, Togias A, et al. Next-generation Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol. 2020 Jan;145(1):70-80.e3.
https://www.jacionline.org/article/S0091-6749(19)31187-X/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/31627910?tool=bestpractice.com
Second-generation, non-sedating antihistamines are recommended for initial treatment of mild symptoms.[3]Dykewicz MS, Wallace DV, Amrol DJ, et al. Rhinitis 2020: a practice parameter update. J Allergy Clin Immunol. 2020 Oct;146(4):721-67.
https://www.jacionline.org/article/S0091-6749(20)31023-X/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/32707227?tool=bestpractice.com
They are considered to be safe and relatively free from adverse effects. Sedation associated with the use of first-generation antihistamines diminishes their utility.
Intranasal corticosteroids remain the single most effective class of medications for treating AR.[3]Dykewicz MS, Wallace DV, Amrol DJ, et al. Rhinitis 2020: a practice parameter update. J Allergy Clin Immunol. 2020 Oct;146(4):721-67.
https://www.jacionline.org/article/S0091-6749(20)31023-X/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/32707227?tool=bestpractice.com
[4]Wallace DV, Dykewicz MS, Bernstein DI, et al. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol. 2008 Aug;122(2 suppl):S1-84.
https://www.jacionline.org/article/S0091-6749(08)01123-8/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/18662584?tool=bestpractice.com
However, for many patients, especially those with mild symptoms, antihistamines may be trialled prior to starting intranasal corticosteroids.[61]Scadding GK, Kariyawasam HH, Scadding G, et al. BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (rev ed 2017). Clin Exp Allergy. 2017 Jul;47(7):856-89.
https://onlinelibrary.wiley.com/doi/10.1111/cea.12953
http://www.ncbi.nlm.nih.gov/pubmed/30239057?tool=bestpractice.com
Second-generation antihistamines (e.g., loratadine and cetirizine) are preferred for breastfeeding mothers.[62]NHS Specialist Pharmacy Service. Which oral antihistamines are safe to use whilst breastfeeding? Apr 2020 [internet publication].
https://www.sps.nhs.uk/articles/which-oral-antihistamines-are-safe-to-use-whilst-breastfeeding
Caution is advised if use of first-generation antihistamines is required in breastfeeding mothers.[62]NHS Specialist Pharmacy Service. Which oral antihistamines are safe to use whilst breastfeeding? Apr 2020 [internet publication].
https://www.sps.nhs.uk/articles/which-oral-antihistamines-are-safe-to-use-whilst-breastfeeding
Case reports and studies report somnolence and irritability in breastfed infants when first-generation antihistamines are taken by the mother.[63]Kok TH, Taitz LS, Bennett MJ, et al. Drowsiness due to clemastine transmitted in breast milk. Lancet. 1982 Apr 17;1(8277):914-5.
http://www.ncbi.nlm.nih.gov/pubmed/6122135?tool=bestpractice.com
Leukotriene receptor antagonists (e.g., montelukast) are an option for patients who have failed or are intolerant of other agents, but they are used infrequently due to lack of efficacy and possible risk of neuropsychiatric events.[3]Dykewicz MS, Wallace DV, Amrol DJ, et al. Rhinitis 2020: a practice parameter update. J Allergy Clin Immunol. 2020 Oct;146(4):721-67.
https://www.jacionline.org/article/S0091-6749(20)31023-X/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/32707227?tool=bestpractice.com
[64]US Food and Drug Administration. FDA drug safety communication: FDA requires Boxed Warning about serious mental health side effects for asthma and allergy drug montelukast (Singulair); advises restricting use for allergic rhinitis. Mar 2020 [internet publication].
https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-boxed-warning-about-serious-mental-health-side-effects-asthma-and-allergy-drug
Allergen avoidance and control
Pollen (grasses, trees, weeds)[65]Australasian Society of Clinical Immunology and Allergy. Allergen minimisation. Mar 2019 [internet publication].
https://www.allergy.org.au/patients/allergy-treatments/allergen-minimisation
Keep windows of homes and cars closed and employ an air conditioner in the recycling/indoor mode.
Minimise time spent outdoors during times of high pollen count, when practical.
Avoid activities known to cause exposure to pollen, such as mowing grass.
Shower after outdoor activities where exposure to pollen is high.
Use recirculated air in the car when pollen levels are high.
Wear sunglasses (to protect eyes from airborne pollen).
Dry bedding and clothing inside or in a tumble dryer.
House dust mite minimisation[65]Australasian Society of Clinical Immunology and Allergy. Allergen minimisation. Mar 2019 [internet publication].
https://www.allergy.org.au/patients/allergy-treatments/allergen-minimisation
[66]Sheikh A, Hurwitz B, Nurmatov U, et al. House dust mite avoidance measures for perennial allergic rhinitis. Cochrane Database Syst Rev. 2010 Jul 7;(7):CD001563.
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001563.pub3/full
http://www.ncbi.nlm.nih.gov/pubmed/20614426?tool=bestpractice.com
Physical measures include heating ventilation, freezing, washing, and barrier methods.
Wash bedding weekly in hot water (>60°C) to kill dust mites and denature the allergens they produce. Hot tumble drying of washed items for an additional 10 minutes after they are dry will kill dust mites.
Cover mattress, pillow, and quilt with dust mite-resistant covers. Wash covers every 2 months.
Remove all soft toys and woollen bedding from the bedroom. Freezing soft toys overnight kills mites but does not remove the allergen; they can then be tumbled in the dryer to help with this.
Where possible replace carpets with hard floors.
Damp dust or use cloths to clean hard surfaces (including hard floors) weekly.
Vacuum carpets weekly.
Reduce humidity – have a dry and well ventilated house, and adequate floor and wall insulation.
Venetian blinds or flat blinds are easier to clean than heavy curtains.
Consider leather or vinyl sofas instead of fabric.
Pet dander
Individuals allergic to cats and dogs have few effective ways to reduce their exposure to pet allergens short of ridding themselves of the animals. It is important to counsel patients that pet allergen levels only slowly decline over several months when a pet is removed from the home; therefore, rapid improvement is not expected.[65]Australasian Society of Clinical Immunology and Allergy. Allergen minimisation. Mar 2019 [internet publication].
https://www.allergy.org.au/patients/allergy-treatments/allergen-minimisation
Ultimately though, the affected individual willing to part with their cat or dog will frequently experience significant symptom relief.
While some people may react differently to individual dogs, 'hypoallergenic' dogs are a myth that has been debunked.[67]Vredegoor DW, Willemse T, Chapman MD, et al. Can f 1 levels in hair and homes of different dog breeds: lack of evidence to describe any dog breed as hypoallergenic. J Allergy Clin Immunol. 2012 Oct;130(4):904-9.e7.
https://www.jacionline.org/article/S0091-6749(12)00793-2/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/22728082?tool=bestpractice.com
[68]Liem O, Kessen K, de Groot H. Hypoallergenic animals, fact or myth? [in Dutch]. Ned Tijdschr Geneeskd. 2019 Dec 31;164:D4298.
http://www.ncbi.nlm.nih.gov/pubmed/32186820?tool=bestpractice.com
Washing of cats has not been shown to be an effective approach to reducing allergen exposure. Although weekly washings can reduce allergens, clinical studies have shown neither a persistent reduction of airborne allergens nor a clear reduction in rhinitis symptoms.[69]Nageotte C, Park M, Havstad S, et al. Duration of airborne Fel d 1 reduction after cat washing. J Allergy Clin Immunol. 2006 Aug;118(2):521-2.
http://www.ncbi.nlm.nih.gov/pubmed/16890781?tool=bestpractice.com
[70]Klucka CV, Ownby DR, Green J, et al. Cat shedding of Fel d I is not reduced by washings, Allerpet-C spray, or acepromazine. J Allergy Clin Immunol. 1995 Jun;95(6):1164-71.
http://www.ncbi.nlm.nih.gov/pubmed/7797784?tool=bestpractice.com
High-efficiency particulate air (HEPA) filters did not lead to significant symptom improvement in controlled trials of cat-sensitised individuals.[71]Sulser C, Schulz G, Wagner P, et al. Can the use of HEPA cleaners in homes of asthmatic children and adolescents sensitized to cat and dog allergens decrease bronchial hyperresponsiveness and allergen contents in solid dust? Int Arch Allergy Immunol. 2009;148(1):23-30.
http://www.ncbi.nlm.nih.gov/pubmed/18716400?tool=bestpractice.com
[72]Wood RA, Johnson EF, Van Natta ML, et al. A placebo-controlled trial of a HEPA air cleaner in the treatment of cat allergy. Am J Respir Crit Care Med. 1998 Jul;158(1):115-20.
http://www.ncbi.nlm.nih.gov/pubmed/9655716?tool=bestpractice.com
Cockroach infestation
Cockroach infestation is associated with AR and asthma, especially in the inner city.[73]Huss K, Adkinson NF Jr, Eggleston PA, et al. House dust mite and cockroach exposure are strong risk factors for positive allergy skin test responses in the Childhood Asthma Management Program. J Allergy Clin Immunol. 2001 Jan;107(1):48-54.
http://www.ncbi.nlm.nih.gov/pubmed/11149990?tool=bestpractice.com
Control measures are based on eliminating suitable environments and restricting access by sealing, caulking, and controlling the food supply as well as using chemical control and traps.
While cockroach extermination by professionals may reduce allergen levels by 80% to 90%, the clinical significance of this finding requires further research.[74]Wood RA, Eggleston PA, Rand C, et al. Cockroach allergen abatement with extermination and sodium hypochlorite cleaning in inner-city homes. Ann Allergy Asthma Immunol. 2001 Jul;87(1):60-4.
http://www.ncbi.nlm.nih.gov/pubmed/11476465?tool=bestpractice.com
Re-infestation from adjacent apartments is a frequent problem, and thus extermination efforts will probably need to be repeated and extended beyond the affected space.
Moulds[65]Australasian Society of Clinical Immunology and Allergy. Allergen minimisation. Mar 2019 [internet publication].
https://www.allergy.org.au/patients/allergy-treatments/allergen-minimisation
Mould-allergic individuals should carefully inspect their home for mould damage, with special attention to more humid areas of the dwelling.
Appropriate steps should be taken to mitigate or prevent sources of humidity and/or water ingress associated with indoor mould growth. Ensure adequate natural ventilation, including the use of extractor fans; seal leaks in bathrooms and roofs.
Clear overflowing gutters and blocked under-floor vents.
Remove indoor pot plants (which promote mould growth).
Dry or remove wet carpets.
Avoid working with garden compost or mulch, or mowing lawns.
Remove localised mould growth with a dilute bleach solution. More extensive mould damage may require aggressive measures such as replacing the affected surface/material.
Mild or intermittent symptoms
First-line management is with either an intranasal corticosteroid or a non-sedating oral antihistamine.[60]Bousquet J, Schünemann HJ, Togias A, et al. Next-generation Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol. 2020 Jan;145(1):70-80.e3.
https://www.jacionline.org/article/S0091-6749(19)31187-X/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/31627910?tool=bestpractice.com
Monotherapy with an intranasal corticosteroid is generally recommended because oral antihistamines are less effective.[60]Bousquet J, Schünemann HJ, Togias A, et al. Next-generation Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol. 2020 Jan;145(1):70-80.e3.
https://www.jacionline.org/article/S0091-6749(19)31187-X/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/31627910?tool=bestpractice.com
[75]Bousquet J, Devillier P, Arnavielhe S, et al. Treatment of allergic rhinitis using mobile technology with real-world data: the MASK observational pilot study. Allergy. 2018 Sep;73(9):1763-74.
https://onlinelibrary.wiley.com/doi/10.1111/all.13406
http://www.ncbi.nlm.nih.gov/pubmed/29336067?tool=bestpractice.com
However, many patients may prefer oral drugs.
Oral antihistamines are effective for rhinorrhoea, sneezing, and itching, but have only a modest effect on nasal congestion.[61]Scadding GK, Kariyawasam HH, Scadding G, et al. BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (rev ed 2017). Clin Exp Allergy. 2017 Jul;47(7):856-89.
https://onlinelibrary.wiley.com/doi/10.1111/cea.12953
http://www.ncbi.nlm.nih.gov/pubmed/30239057?tool=bestpractice.com
Cetirizine, a second-generation antihistamine, has been found to be particularly effective in AR, but may cause some mild sedation.[76]Xiao J, Wu WX, Ye YY, et al. A network meta-analysis of randomized controlled trials focusing on different allergic rhinitis medications. Am J Ther. 2016 Nov/Dec;23(6):e1568-78.
http://www.ncbi.nlm.nih.gov/pubmed/25867532?tool=bestpractice.com
Second-generation oral antihistamines are preferred to first-generation agents because they cause less sedation, dizziness, and incoordination.[3]Dykewicz MS, Wallace DV, Amrol DJ, et al. Rhinitis 2020: a practice parameter update. J Allergy Clin Immunol. 2020 Oct;146(4):721-67.
https://www.jacionline.org/article/S0091-6749(20)31023-X/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/32707227?tool=bestpractice.com
Paradoxical hyperactivity with use of sedating antihistamines has been reported, particularly in children.[77]New Zealand Medicines and Medical Devices Safety Authority (Medsafe). Children and sedating antihistamines. Mar 2013 [internet publication].
https://www.medsafe.govt.nz/profs/PUArticles/Mar2013ChildrenAndSedatingAntihistamines.htm
Intranasal antihistamines are another first-line option when symptoms are intermittent and do not require daily medication.[3]Dykewicz MS, Wallace DV, Amrol DJ, et al. Rhinitis 2020: a practice parameter update. J Allergy Clin Immunol. 2020 Oct;146(4):721-67.
https://www.jacionline.org/article/S0091-6749(20)31023-X/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/32707227?tool=bestpractice.com
Intranasal antihistamines are particularly effective for rhinorrhoea and congestion, but they do not improve symptoms at non-nasal sites.[78]Wise SK, Lin SY, Toskala E, et al. International consensus statement on allergy and rhinology: allergic rhinitis. Int Forum Allergy Rhinol. 2018 Feb;8(2):108-352.
https://onlinelibrary.wiley.com/doi/full/10.1002/alr.22073
http://www.ncbi.nlm.nih.gov/pubmed/29438602?tool=bestpractice.com
They have a fast onset of action after initial dosing (usually 15-30 minutes, and no later than 3 hours) and are effective over a 12-hour period.[3]Dykewicz MS, Wallace DV, Amrol DJ, et al. Rhinitis 2020: a practice parameter update. J Allergy Clin Immunol. 2020 Oct;146(4):721-67.
https://www.jacionline.org/article/S0091-6749(20)31023-X/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/32707227?tool=bestpractice.com
[60]Bousquet J, Schünemann HJ, Togias A, et al. Next-generation Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol. 2020 Jan;145(1):70-80.e3.
https://www.jacionline.org/article/S0091-6749(19)31187-X/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/31627910?tool=bestpractice.com
Intranasal antihistamines may cause sedation.
Patient re-assessment
The patient should be re-assessed after a trial of monotherapy with an intranasal corticosteroid or oral antihistamine (ideally within 5 to 7 days).[3]Dykewicz MS, Wallace DV, Amrol DJ, et al. Rhinitis 2020: a practice parameter update. J Allergy Clin Immunol. 2020 Oct;146(4):721-67.
https://www.jacionline.org/article/S0091-6749(20)31023-X/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/32707227?tool=bestpractice.com
If the patient remains symptomatic, an alternative first-line monotherapy should be used.[3]Dykewicz MS, Wallace DV, Amrol DJ, et al. Rhinitis 2020: a practice parameter update. J Allergy Clin Immunol. 2020 Oct;146(4):721-67.
https://www.jacionline.org/article/S0091-6749(20)31023-X/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/32707227?tool=bestpractice.com
Failing this, first-line treatment options (from different drug classes) may be combined. For example, an intranasal corticosteroid or intranasal antihistamine could be added to an oral antihistamine. If symptoms are persistent, an intranasal corticosteroid and intranasal antihistamine may be continued in combination.[60]Bousquet J, Schünemann HJ, Togias A, et al. Next-generation Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol. 2020 Jan;145(1):70-80.e3.
https://www.jacionline.org/article/S0091-6749(19)31187-X/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/31627910?tool=bestpractice.com
When symptoms improve, decreasing or discontinuing treatment may be considered.[3]Dykewicz MS, Wallace DV, Amrol DJ, et al. Rhinitis 2020: a practice parameter update. J Allergy Clin Immunol. 2020 Oct;146(4):721-67.
https://www.jacionline.org/article/S0091-6749(20)31023-X/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/32707227?tool=bestpractice.com
[60]Bousquet J, Schünemann HJ, Togias A, et al. Next-generation Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol. 2020 Jan;145(1):70-80.e3.
https://www.jacionline.org/article/S0091-6749(19)31187-X/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/31627910?tool=bestpractice.com
The dose of intranasal sprays can be reduced as long as symptoms continue to be controlled. If multiple pharmacological agents are used, discontinuation of the medication added to the intranasal corticosteroid may be considered.
Patients may have tried using over-the-counter decongestants, which may provide temporary relief from symptoms; however, there is no evidence to support their ongoing use in allergic rhinitis, and guidelines do not recommend them.
Persistent and moderate or severe symptoms
Intranasal corticosteroids should be the first consideration if symptoms are persistent and moderate or severe.[3]Dykewicz MS, Wallace DV, Amrol DJ, et al. Rhinitis 2020: a practice parameter update. J Allergy Clin Immunol. 2020 Oct;146(4):721-67.
https://www.jacionline.org/article/S0091-6749(20)31023-X/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/32707227?tool=bestpractice.com
They may provide additional benefit in reducing AR-associated ocular symptoms.[79]Blaiss MS. Evolving paradigm in the management of allergic rhinitis-associated ocular symptoms: role of intranasal corticosteroids. Curr Med Res Opin. 2008 Mar;24(3):821-36.
http://www.ncbi.nlm.nih.gov/pubmed/18257976?tool=bestpractice.com
[80]Naclerio R. Intranasal corticosteroids reduce ocular symptoms associated with allergic rhinitis. Otolaryngol Head Neck Surg. 2008 Feb;138(2):129-39.
http://www.ncbi.nlm.nih.gov/pubmed/18241703?tool=bestpractice.com
Oral and intranasal antihistamines are also first-line options in these patients.
The patient should be re-assessed after a trial of monotherapy with an intranasal corticosteroid or oral antihistamine (ideally within 5-7 days).[3]Dykewicz MS, Wallace DV, Amrol DJ, et al. Rhinitis 2020: a practice parameter update. J Allergy Clin Immunol. 2020 Oct;146(4):721-67.
https://www.jacionline.org/article/S0091-6749(20)31023-X/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/32707227?tool=bestpractice.com
If the patient remains symptomatic, an alternative first-line monotherapy should be used.[3]Dykewicz MS, Wallace DV, Amrol DJ, et al. Rhinitis 2020: a practice parameter update. J Allergy Clin Immunol. 2020 Oct;146(4):721-67.
https://www.jacionline.org/article/S0091-6749(20)31023-X/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/32707227?tool=bestpractice.com
Failing this, first-line treatment options (from different drug classes) may be combined. For example, an intranasal corticosteroid or intranasal antihistamine could be added to an oral antihistamine. If symptoms are persistent, an intranasal corticosteroid and intranasal antihistamine may be continued in combination.[60]Bousquet J, Schünemann HJ, Togias A, et al. Next-generation Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol. 2020 Jan;145(1):70-80.e3.
https://www.jacionline.org/article/S0091-6749(19)31187-X/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/31627910?tool=bestpractice.com
When symptoms improve, decreasing or discontinuing treatment may be considered.[3]Dykewicz MS, Wallace DV, Amrol DJ, et al. Rhinitis 2020: a practice parameter update. J Allergy Clin Immunol. 2020 Oct;146(4):721-67.
https://www.jacionline.org/article/S0091-6749(20)31023-X/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/32707227?tool=bestpractice.com
[60]Bousquet J, Schünemann HJ, Togias A, et al. Next-generation Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol. 2020 Jan;145(1):70-80.e3.
https://www.jacionline.org/article/S0091-6749(19)31187-X/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/31627910?tool=bestpractice.com
The dose of intranasal sprays can be reduced as long as symptoms continue to be controlled. If multiple pharmacological agents are used, discontinuation of the medication added to the intranasal corticosteroid may be considered.
Immunotherapy
Immunotherapy may be offered by an allergy specialist (through a shared decision-making model) to a patient who remains symptomatic despite allergen avoidance measures and pharmacotherapy.[3]Dykewicz MS, Wallace DV, Amrol DJ, et al. Rhinitis 2020: a practice parameter update. J Allergy Clin Immunol. 2020 Oct;146(4):721-67.
https://www.jacionline.org/article/S0091-6749(20)31023-X/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/32707227?tool=bestpractice.com
Immunotherapy is also commonly used by patients either unwilling to take or unable to tolerate medications.[3]Dykewicz MS, Wallace DV, Amrol DJ, et al. Rhinitis 2020: a practice parameter update. J Allergy Clin Immunol. 2020 Oct;146(4):721-67.
https://www.jacionline.org/article/S0091-6749(20)31023-X/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/32707227?tool=bestpractice.com
Immunotherapy should be targeted to include allergens that are clinically relevant to both the patient and the geographic locale.
Allergen immunotherapy has been shown to improve symptoms, medication use, and combined symptom/medication use scores in patients with rhinoconjunctivitis.[81]Dhami S, Nurmatov U, Arasi S, et al. Allergen immunotherapy for allergic rhinoconjunctivitis: a systematic review and meta-analysis. Allergy. 2017 Nov;72(11):1597-631.
https://onlinelibrary.wiley.com/doi/full/10.1111/all.13201
http://www.ncbi.nlm.nih.gov/pubmed/28493631?tool=bestpractice.com
[82]Radulovic S, Calderon MA, Wilson D, et al. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev. 2010 Dec 8;(12):CD002893.
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002893.pub2/full
http://www.ncbi.nlm.nih.gov/pubmed/21154351?tool=bestpractice.com
Subcutaneous immunotherapy (SCIT) may alter the natural history of allergic disease (induce long-term remission after discontinuation of therapy and prevent new sensitisations), as well as reduce the progression from AR to asthma when given in children aged 6 to 14 years for a minimum of 3 years.[83]Jacobsen L, Niggemann B, Dreborg S, et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy. 2007 Aug;62(8):943-8.
http://www.ncbi.nlm.nih.gov/pubmed/17620073?tool=bestpractice.com
Sublingual immunotherapy (SLIT), an alternative to SCIT depending on the allergen involved, is effective in treating AR in adults and children and may also have disease-modifying potential.[82]Radulovic S, Calderon MA, Wilson D, et al. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev. 2010 Dec 8;(12):CD002893.
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002893.pub2/full
http://www.ncbi.nlm.nih.gov/pubmed/21154351?tool=bestpractice.com
[84]Durham SR, Emminger W, Kapp A, et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol. 2012 Mar;129(3):717-25.e5.
https://www.jacionline.org/article/S0091-6749(11)02942-3/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/22285278?tool=bestpractice.com
[85]Dretzke J, Meadows A, Novielli N, et al. Subcutaneous and sublingual immunotherapy for seasonal allergic rhinitis: a systematic review and indirect comparison. J Allergy Clin Immunol. 2013 May;131(5):1361-6.
https://www.jacionline.org/article/S0091-6749(13)00323-0/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/23557834?tool=bestpractice.com
[86]Lin SY, Erekosima N, Kim JM, et al. Sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review. JAMA. 2013 Mar 27;309(12):1278-88.
https://jamanetwork.com/journals/jama/fullarticle/1672214
http://www.ncbi.nlm.nih.gov/pubmed/23532243?tool=bestpractice.com
[87]Durham SR, Creticos PS, Nelson HS, et al. Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: pooled analyses. J Allergy Clin Immunol. 2016 Oct;138(4):1081-8.
https://www.jacionline.org/article/S0091-6749(16)30614-5/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/27527264?tool=bestpractice.com
[88]Di Bona D, Plaia A, Leto-Barone MS, et al. Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a meta-analysis-based comparison. J Allergy Clin Immunol. 2012 Nov;130(5):1097-107.e2.
http://www.ncbi.nlm.nih.gov/pubmed/23021885?tool=bestpractice.com
[
]
What are the benefits and harms of sublingual immunotherapy compared with placebo in people with allergic rhinitis?/cca.html?targetUrl=https://cochranelibrary.com/cca/doi/10.1002/cca.237/fullShow me the answer It is considered to be safer than SCIT because adverse effects are usually limited to mucosal symptoms, and it is easier to administer (patient self-administers).[89]Canonica GW, Cox L, Pawankar R, et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J. 2014 Mar 28;7(1):6.
https://www.worldallergyorganizationjournal.org/article/S1939-4551(19)30238-8/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/24679069?tool=bestpractice.com
However, SLIT may be less effective than SCIT.[88]Di Bona D, Plaia A, Leto-Barone MS, et al. Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a meta-analysis-based comparison. J Allergy Clin Immunol. 2012 Nov;130(5):1097-107.e2.
http://www.ncbi.nlm.nih.gov/pubmed/23021885?tool=bestpractice.com
Direct comparisons using standardised and validated outcome measures between SLIT and SCIT are not available.[90]Calderon MA, Eichel A, Makatsori M, et al. Comparability of subcutaneous and sublingual immunotherapy outcomes in allergic rhinitis clinical trials. Curr Opin Allergy Clin Immunol. 2012 Jun;12(3):249-56.
http://www.ncbi.nlm.nih.gov/pubmed/22499145?tool=bestpractice.com
SLIT is more appropriately used in monosensitised patients, especially those sensitised to dust mites, grass, or ragweed.[91]Demoly P, Emminger W, Rehm D, et al. Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: results from a randomized double-blind, placebo-controlled phase III trial. J Allergy Clin Immunol. 2016 Feb;137(2):444-51.e8.
https://www.jacionline.org/article/S0091-6749%2815%2900935-5/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/26292778?tool=bestpractice.com
[92]Blaiss M, Maloney J, Nolte H, et al. Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents. J Allergy Clin Immunol. 2011 Jan;127(1):64-71, 71.e1-4.
http://www.ncbi.nlm.nih.gov/pubmed/21211642?tool=bestpractice.com
[93]Durham SR; GT-08 investigators. Sustained effects of grass pollen AIT. Allergy. 2011 Jul;66 (Suppl 95):50-2.
http://www.ncbi.nlm.nih.gov/pubmed/21668855?tool=bestpractice.com
[94]Nelson HS, Nolte H, Creticos P, et al. Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults. J Allergy Clin Immunol. 2011 Jan;127(1):72-80, 80.e1-2.
http://www.ncbi.nlm.nih.gov/pubmed/21211643?tool=bestpractice.com
[95]Creticos PS, Esch RE, Couroux P, et al. Randomized, double-blind, placebo-controlled trial of standardized ragweed sublingual-liquid immunotherapy for allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2014 Mar;133(3):751-8.
https://www.jacionline.org/article/S0091-6749(13)01702-8/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/24332263?tool=bestpractice.com
If immunotherapy is not available or there is a significant wait, a short course (7 days) of an oral corticosteroid may also be considered if symptoms are severe.[60]Bousquet J, Schünemann HJ, Togias A, et al. Next-generation Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol. 2020 Jan;145(1):70-80.e3.
https://www.jacionline.org/article/S0091-6749(19)31187-X/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/31627910?tool=bestpractice.com
Usual therapy not effective
Evaluation by an allergy consultant is advisable when there is:
An incomplete response to trial of therapy of environmental and pharmacological interventions, and a persistent and significant impact on quality of life (interference with hobbies, family life, activities of daily living, sleep, emotional well-being)
An inability to adequately control associated conditions such as asthma or sinus disease.